Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma

Background: The performance of immune checkpoint inhibitor (ICI) monotherapy was proved to be disappointing in pancreatic ductal adenocarcinoma (PDAC). Increasing evidence has shown the promising efficacy of ICIs combined with systemic therapy in the first-line treatment in solid tumors. Case presen...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Front Immunol
Prif Awduron: Shui, Lin, Cheng, Ke, Li, Xiaofen, Shui, Pixian, Li, Shuangshuang, Peng, Yang, Li, Jian, Guo, Fengzhu, Yi, Cheng, Cao, Dan
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Frontiers Media S.A. 2020
Pynciau:
Immunology
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318868/
https://ncbi.nlm.nih.gov/pubmed/32636837
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01127
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg